Mesenchymal stem cells as novel micro-ribonucleic acid delivery vehicles in kidney disease

Nephrology

Volumn 21, Issue 5, 2016, Pages 363-371

  Yao, Kevin ^a   Ricardo, Sharon D ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

exosome; kidney fibrosis; mesenchymal stem cells; miRNA

Indexed keywords

GROWTH FACTOR; MICRORNA; MICRORNA 21; MICRORNA 29; MICRORNA LET 7; UNCLASSIFIED DRUG;

CELL ENGINEERING; CELL MIGRATION; CELL POLARITY; CELL TRANSDIFFERENTIATION; CHRONIC KIDNEY DISEASE; EXOSOME; FREEZE THAWING; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; LIPOSOMAL GENE DELIVERY SYSTEM; LIVER CANCER; MACROPHAGE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT SAFETY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN SECRETION; RENAL PROTECTION; REVIEW; RNA SYNTHESIS; SIGNAL TRANSDUCTION; STEM CELL GENE THERAPY; TISSUE REPAIR; VIRAL GENE DELIVERY SYSTEM; ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETICS; KIDNEY; KIDNEY DISEASES; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PROCEDURES;

ANIMALS; FIBROSIS; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; KIDNEY; KIDNEY DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICRORNAS;

EID: 84964273539     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12643     Document Type: Review

References (116)

1. Stevens LA, Viswanathan G, Weiner DE,. Chronic kidney disease and end-stage renal disease in the elderly population: current prevalence, future projections, and clinical significance. Adv. Chronic Kidney Dis. 2010; 17 (4): 293-301.
2. Jha V, et al., Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382 (9888): 260-72.
3. Wynn TA,. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest. 2007; 117 (3): 524-9.
4. Hewitson TD,. Renal tubulointerstitial fibrosis: common but never simple. Am. J. Physiol-Ren. Physiol. 2009; 296 (6): F1239-F1244.
5. Lee RC, Feinbaum RL, Ambros V,. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75 (5): 843-854.
6. Millar AA, Waterhouse PM,. Plant and animal microRNAs: similarities and differences. Funct. Integr. Genomics 2005; 5 (3): 129-35.
7. Kawahara Y,. Human diseases caused by germline and somatic abnormalities in microRNA and microRNA-related genes. Congenit. Anom. 2014; 54 (1): 12-21.
8. Lewis BP, Burge CB, Bartel DP,. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120 (1): 15-20.
9. Hwang HW, Mendell JT,. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 2006; 94 (6): 776-80.
10. Pandey P, et al., Microarray-based approach identifies microRNAs and their target functional patterns in polycystic kidney disease. BMC Genomics 2008; 9: 624.
11. Kato M, et al., A microRNA circuit mediates transforming growth factor-beta1 autoregulation in renal glomerular mesangial cells. Kidney Int. 2011; 80 (4): 358-68.
12. Gottardo F, et al., Micro-RNA profiling in kidney and bladder cancers. Urol. Oncol. 2007; 25 (5): 387-92.
13. Rodriguez A, et al., Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004; 14 (10a): 1902-10.
14. Lee Y, et al., MicroRNA genes are transcribed by RNA polymerase II. Embo J 2004; 23 (20): 4051-60.
15. Zeng Y, Yi R, Cullen BR,. Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha. Embo J 2005; 24 (1): 138-48.
16. Ando Y, et al., Two-step cleavage of hairpin RNA with 5′ overhangs by human DICER. BMC Mol. Biol. 2011; 12: 6.
17. Flores-Jasso CF, et al., First step in pre-miRNAs processing by human Dicer. Acta Pharmacol. Sin. 2009; 30 (8): 1177-85.
18. Guo L, Lu Z,. The Fate of miRNA∗ Strand through Evolutionary Analysis: Implication for Degradation As Merely Carrier Strand or Potential Regulatory Molecule? PLoS One 2010; 5 (6): e11387.
19. Lambert NJ, Gu SG, Zahler AM,. The conformation of microRNA seed regions in native microRNPs is prearranged for presentation to mRNA targets. Nucleic Acids Res. 2011; 39 (11): 4827-35.
20. Broderick JA, Zamore PD,. MicroRNA therapeutics. Gene Ther. 2011; 18 (12): 1104-1110.
21. Jing Q, et al., Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 2005; 120 (5): 623-34.
22. Djuranovic S, Nahvi A, Green R,. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay. Science 2012; 336 (6078): 237-40.
23. Wu L, Fan J, Belasco JG,. MicroRNAs direct rapid deadenylation of mRNA. Proc. Natl. Acad. Sci. U. S. A. 2006; 103 (11): 4034-9.
24. Nishihara T, et al., miRISC recruits decapping factors to miRNA targets to enhance their degradation. Nucleic Acids Res. 2013; 41 (18): 8692-705.
25. Jones CI, Zabolotskaya MV, Newbury SF,. The 5′ - > 3′ exoribonuclease XRN1/Pacman and its functions in cellular processes and development. Wiley Interdiscip. Rev. RNA 2012; 3 (4): 455-68.
26. Valencia-Sanchez MA, et al., Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006; 20 (5): 515-24.
27. Wang B, et al., Transforming growth factor-[beta]1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 2014; 85 (2): 352-361.
28. Chau BN, et al., MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 2012; 4 (121): 121ra18.
29. Wang B, et al., Suppression of microRNA-29 Expression by TGF-β1 Promotes Collagen Expression and Renal Fibrosis. J. Am. Soc. Nephrol. 2012; 23 (2): 252-265.
30. Brennan EP, et al., Lipoxins attenuate renal fibrosis by inducing let-7c and suppressing TGFbetaR1. J. Am. Soc. Nephrol. 2013; 24 (4): 627-37.
31. Gomez IG, et al., Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 2014; 125 (1): 141-56.
32. Zhong X, et al., miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 2013; 56 (3): 663-74.
33. Liu G, et al., miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 2010; 207 (8): 1589-97.
34. Cheng J, et al., Identification of collagen 1 as a post-transcriptional target of miR-29b in skin fibroblasts: therapeutic implication for scar reduction. Am. J. Med. Sci. 2013; 346 (2): 98-103.
35. Long J, et al., MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J. Biol. Chem. 2011; 286 (13): 11837-48.
36. Reinhart BJ, et al., The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000; 403 (6772): 901-6.
37. Pasquinelli AE, et al., Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408 (6808): 86-9.
38. Banerjee S, et al., MicroRNA let-7c regulates macrophage polarization. J. Immunol. 2013; 190 (12): 6542-9.
39. Meng F, et al., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133 (2): 647-58.
40. Medina PP, Nolde M, Slack FJ,. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467 (7311): 86-90.
41. Thum T, et al., MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456 (7224): 980-4.
42. Zarjou A, et al., Identification of a microRNA signature in renal fibrosis: role of miR-21. Am. J. Physiol. Renal Physiol. 2011; 301 (4): F793-F801.
43. Li JH, et al., Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J. Am. Soc. Nephrol. 2002; 13 (6): 1464-72.
44. Glowacki F, et al., Increased Circulating miR-21 Levels Are Associated with Kidney Fibrosis. PLoS One 2013; 8 (2): e58014.
45. van Rooij E, et al., Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl. Acad. Sci. 2008; 105 (35): 13027-13032.
46. Roderburg C, et al., Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53 (1): 209-18.
47. Xiao J, et al., miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol. Ther. 2012; 20 (6): 1251-60.
48. Qin W, et al., TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J. Am. Soc. Nephrol. 2011; 22 (8): 1462-74.
49. Chung AC, et al., Smad7 suppresses renal fibrosis via altering expression of TGF-beta/Smad3-regulated microRNAs. Mol. Ther. 2013; 21 (2): 388-98.
50. Chen HY, et al., MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 2014; 22 (4): 842-53.
51. Mitchell PS, et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. 2008; 105 (30): 10513-10518.
52. Chen X, et al., Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18 (10): 997-1006.
53. Arroyo JD, et al., Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011; 108 (12): 5003-8.
54. Valadi H, et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007; 9 (6): 654-9.
55. Singh S, Narang AS, Mahato RI,. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 2011; 28 (12): 2996-3015.
56. Jenks S,. Gene Therapy Death-"Everyone Has to Share in the Guilt". J. Natl. Cancer Inst. 2000; 92 (2): 98-100.
57. Russell WC,. Update on adenovirus and its vectors. J. Gen. Virol. 2000; 81 (Pt 11): 2573-604.
58. McTaggart S, Al-Rubeai M,. Retroviral vectors for human gene delivery. Biotechnol. Adv. 2002; 20 (1): 1-31.
59. Hacein-Bey-Abina S, et al., Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008; 118 (9): 3132-3142.
60. Wong LF, et al., Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum. Gene Ther. 2006; 17 (1): 1-9.
61. Follenzi A, Santambrogio L, Annoni A,. Immune responses to lentiviral vectors. Curr. Gene Ther. 2007; 7 (5): 306-15.
62. Torchilin VP,. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005; 4: 145+.
63. Ando H, et al., Polycation liposomes as a vector for potential intracellular delivery of microRNA. J. Gene Med. 2013; 15 (10): 375-83.
64. Buyens K, et al., Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control. Release 2012; 158 (3): 362-70.
65. Immordino ML, Dosio F, Cattel L,. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 2006; 1 (3): 297-315.
66. English K, Mahon BP,. Allogeneic mesenchymal stem cells: agents of immune modulation. J. Cell. Biochem. 2011; 112 (8): 1963-8.
67. Bai ZM, et al., Arterially transplanted mesenchymal stem cells in a mouse reversible unilateral ureteral obstruction model: in vivo bioluminescence imaging and effects on renal fibrosis. Chin Med J (Engl) 2013; 126 (10): 1890-4.
68. Huuskes BM, et al., Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy. Faseb J 2015; 29 (2): 540-53.
69. Choi SJ, Kim JK, Hwang SD,. Mesenchymal stem cell therapy for chronic renal failure. Expert Opin. Biol. Ther. 2010; 10 (8): 1217-26.
70. Marshall E,. Gene therapy death prompts review of adenovirus vector. Science 1999; 286 (5448): 2244-5.
71. Giacca M, Zacchigna S,. Virus-mediated gene delivery for human gene therapy. J. Control. Release 2012; 161 (2): 377-88.
72. Seow Y, Wood MJ,. Biological gene delivery vehicles: beyond viral vectors. Mol. Ther. 2009; 17 (5): 767-77.
73. Humphreys BD, Bonventre JV,. Mesenchymal stem cells in acute kidney injury. Annu. Rev. Med. 2008; 59: 311-25.
74. Narbona-Carceles J, et al., Bone marrow mesenchymal stem cell aspirates from alternative sources: is the knee as good as the iliac crest? Injury 2014; 45 (Suppl 4): S42-7.
75. Friedenstein AJ, Gorskaja JF, Kulagina NN,. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 1976; 4 (5): 267-74.
76. Wang D, et al., Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann. Rheum. Dis. 2011; 70 (7): 1285-8.
77. Dominici M, et al., Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (4): 315-7.
78. Caplan AI, Dennis JE,. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 2006; 98 (5): 1076-84.
79. Karp JM, Leng Teo GS,. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009; 4 (3): 206-16.
80. Asanuma H, et al., Arterially delivered mesenchymal stem cells prevent obstruction-induced renal fibrosis. J. Surg. Res. 2011; 168 (1): e51-9.
81. Yang HC, Zuo Y, Fogo AB,. Models of chronic kidney disease. Drug Discov. Today Dis. Model 2010; 7 (1-2): 13-19.
82. Sohni A, Verfaillie CM,. Mesenchymal Stem Cells Migration Homing and Tracking. Stem Cell Int. 2013; 2013: 8.
83. Ponte AL, et al., The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007; 25 (7): 1737-45.
84. Guo J, et al., Insulin-like growth factor 1 improves the efficacy of mesenchymal stem cells transplantation in a rat model of myocardial infarction. J. Biomed. Sci. 2008; 15 (1): 89-97.
85. Huang Y-l, et al., Effects of insulin-like growth factor-1 on the properties of mesenchymal stem cells in vitro. J. Zhejiang University Sci. B 2012; 13 (1): 20-28.
86. Bian XH, et al., The Role of CD44-Hyaluronic Acid Interaction in Exogenous Mesenchymal Stem Cells Homing to Rat Remnant Kidney. Kidney Blood Press. Res. 2013; 38 (1): 11-20.
87. Herrera MB, et al., Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007; 72 (4): 430-41.
88. Choi S, et al., The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells Dev. 2009; 18 (3): 521-9.
89. Sangidorj O, et al., Bone marrow-derived endothelial progenitor cells confer renal protection in a murine chronic renal failure model. Am. J. Physiol. Renal Physiol. 2010; 299 (2): F325-35.
90. Lee SR, et al., Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren. Fail. 2010; 32 (7): 840-8.
91. Bi B, et al., Stromal cells protect against acute tubular injury via an endocrine effect. J. Am. Soc. Nephrol. 2007; 18 (9): 2486-96.
92. Togel F, et al., Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am. J. Physiol. Renal Physiol. 2005; 289 (1): F31-42.
93. van Koppen A, et al., Human embryonic mesenchymal stem cell-derived conditioned medium rescues kidney function in rats with established chronic kidney disease. PLoS One 2012; 7 (6): e38746.
94. Wise AF, et al., Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia/reperfusion injury. Am. J. Physiol. Renal Physiol. 2014; 306 (10): F1222-35.
95. Crisostomo PR, et al., Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am. J. Physiol. Cell Physiol. 2008; 294 (3): C675-82.
96. Imberti B, et al., Insulin-like growth factor-1 sustains stem cell mediated renal repair. J. Am. Soc. Nephrol. 2007; 18 (11): 2921-8.
97. Gong R, Rifai A, Dworkin LD,. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J. Am. Soc. Nephrol. 2006; 17 (9): 2464-73.
98. Togel F, et al., Autologous and allogeneic marrow stromal cells are safe and effective for the treatment of acute kidney injury. Stem Cells Dev. 2009; 18 (3): 475-85.
99. Nemeth K, et al., Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009; 15 (1): 42-9.
100. Gao S, et al., Mouse bone marrow-derived mesenchymal stem cells induce macrophage M2 polarization through the nuclear factor-kappaB and signal transducer and activator of transcription 3 pathways. Exp. Biol. Med. (Maywood) 2014; 239 (3): 366-75.
101. Mills CD,. M1 and M2 Macrophages: Oracles of Health and Disease. Crit. Rev. Immunol. 2012; 32 (6): 463-88.
102. Lai RC, et al., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 2010; 4 (3): 214-22.
103. Bruno S, et al., Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J. Am. Soc. Nephrol. 2009; 20 (5): 1053-67.
104. Lakhal S, Wood MJA,. Exosome nanotechnology: An emerging paradigm shift in drug delivery. Bioessays 2011; 33 (10): 737-741.
105. Thébaud B, Stewart DJ,. Exosomes: Cell Garbage Can, Therapeutic Carrier, or Trojan Horse? Circulation 2012; 126 (22): 2553-5.
106. Greening DW, et al., A protocol for exosome isolation and characterization: evaluation of ultracentrifugation, density-gradient separation, and immunoaffinity capture methods. Methods Mol. Biol. 2015; 1295: 179-209.
107. Zhou Y, et al., Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res. Ther. 2013; 4 (2): 34.
108. Bitzer M, Ben-Dov IZ, Thum T,. Microparticles and microRNAs of endothelial progenitor cells ameliorate acute kidney injury. Kidney Int. 2012; 82 (4): 375-377.
109. Mittelbrunn M, et al., Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat. Commun. 2011; 2: 282.
110. Koh W, et al., Analysis of deep sequencing microRNA expression profile from human embryonic stem cells derived mesenchymal stem cells reveals possible role of let-7 microRNA family in downstream targeting of hepatic nuclear factor 4 alpha. BMC Genomics 2010; 11 (Suppl 1): S6.
111. Porada CD, Almeida-Porada G,. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv. Drug Deliv. Rev. 2010; 62 (12): 1156-66.
112. Feng D, et al., Cellular internalization of exosomes occurs through phagocytosis. Traffic 2010; 11 (5): 675-87.
113. Lin P, et al., Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities. Stem Cells Transl. Med. 2012; 1 (12): 886-97.
114. Lee HK, et al., Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget 2013; 4 (2): 346-61.
115. Vanikar AV, Trivedi HL,. Stem cell transplantation in living donor renal transplantation for minimization of immunosuppression. Transplantation 2012; 94 (8): 845-50.
116. Kuroda Y, et al., Unique multipotent cells in adult human mesenchymal cell populations. Proc. Natl. Acad. Sci. 2010; 107 (19): 8639-8643.